<DOC>
	<DOCNO>NCT01419665</DOCNO>
	<brief_summary>The purpose study demonstrate comparability ORR patient previously untreated , advanced stage FL receive GP2013-treatment patient receive MabThera-treatment .</brief_summary>
	<brief_title>GP2013 Treatment Patients With Previously Untreated , Advanced Stage Follicular Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Patient previously untreated advanced stage , CD20positive FL Patient ECOG performance status 0 , 1 2 . Patient Grade 3b ( aggressive ) FL histology FL grade 1 , 2 3a Patient previously receive prior therapy lymphoma Patient evidence uncontrolled , active infection ( viral , bacterial fungal ) . Patient malignancy within 5 year prior date randomization , exception adequately treat situ carcinoma cervix uterus , basal squamous cell carcinoma nonmelanomatous skin cancer . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Follicular Lymphoma</keyword>
	<keyword>Biosimilar</keyword>
	<keyword>GP13-301</keyword>
	<keyword>rituximab</keyword>
	<keyword>Antibodies</keyword>
	<keyword>CD20</keyword>
</DOC>